October 18th, 2019: “EURETINA-Brief”© Issue No. 200

by Dr. Gearóid Tuohy

 

 

Dear EURETINA Members,

 

A very warm welcome to the October 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

 

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

 

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including research has shown that systematic reviews for retinal and vitreous conditions are classified as “not reliable”; a Phase II study results on intravitreal (IVT) pegcetacoplan (a synthetic cyclic peptide) for the treatment of geographic atrophy (GA) secondary to ARMD, and; an announcement from Novartis that FDA brolucizumab injection approves to be noninferior to aflibercept in Phase III studies

 

Finally, our feature bio-ophthalmology article reports on the need for expert research scientists to support the evaluation of new drug approvals for novel technologies, including retinal stem cell and gene therapies. The pace of new technology and novel medical treatments has reached a point at which regulators and assessors require additional expert evaluation in reviewing and assessing marketing authorizations.  Specialist researchers in fields such as genetics, stem cell biology, gene editing and others, are required to assist regulators assess and evaluate new therapies that rapidly progress from academic research to clinical application.  Recent examples include on the submission of a marketing application to the European Medicines Agency for Investigational “LUXTURNA” (voretigene neparvovec).  The application arises from several years research involving academic, regulatory and industry experts to devise a therapy to treat RPE-65 related retinopathies.

 

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

 

Best wishes,

Dr. Gearóid Tuohy, EURETINA

10 thoughts on “October 18th, 2019: “EURETINA-Brief”© Issue No. 200”

  1. Excellent blog here! Also your web site loads up very fast!

    What host are you using? Can I get your affiliate link to your host?
    I wish my site loaded up as fast as yours lol

  2. My brother recommended I would possibly like this web site.
    He was totally right. This submit truly made my day.

    You can not imagine just how a lot time I had spent for this information!
    Thanks!

  3. I just want to tell you that I am new to blogging and site-building and truly enjoyed your page. Likely I’m planning to bookmark your site . You definitely come with fantastic article content. Kudos for sharing your web site.

  4. Today, I went to the beach with my kids. I found a sea shell and gave it to my 4 year old daughter and said “You can hear the ocean if you put this to your ear.” She put the shell to her ear and screamed. There was a hermit crab inside and it pinched her ear. She never wants to go back! LoL I know this is totally off topic but I had to tell someone!

  5. п»їexcellent submit, I love it. I also buy ambien a good deal. You must buy ambien also. I will travel to the whole USA and buy ambien there and in other locations to. i will be downtown, you know for what ? just to buy ambien. I will rest a great deal soon after buy ambien and that it always make me feel so great. I will be buy ambien in a pharmacy or a different destinations, no matter what the daily life get me .

  6. There are some intriguing points in this short article however I don?t understand if I see every one of them facility to heart. There is some validity but I will hold viewpoint till I check out it even more. Excellent article, many thanks and we desire much more! Contributed to FeedBurner as well

Leave a Reply

Your email address will not be published.